Long-term safety of Entyvio for treating ulcerative colitis or Crohn’s Disease

Trial ID:
IRB-16-6868
Gauree G Konijeti, MD, MPH
This is an observational study to assess the long-term safety of Entyvio (vedolizumab), or other similar biologic agents in patients with Ulcerative Colitis...

Inclusion Criteria

  • Be at least 18 years of age
  • Be starting treatment with vedolizmnab (Entyvio) or any biologic agent for UC or CD

Exclusion Criteria

  • Have received any prior treatment with vedolizumab (Entyvio)
  • Be enrolled in another clinical trial that involves treatment for UC or CD

Additional Info

  • Subjects will be asked to complete 2 questionnaires to evaluate their health status at every office visit and will continue to be routinely followed-up by their physician about every 6 months.

Contact Info:

  • Shannon Cyhan
  • cyhan.shannon@scrippshealth.org